| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/02/2008 | CN101152565A Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| 04/02/2008 | CN101152564A Method for preparing compound biotin chitosan film and application of the same in reactivation of periodontium |
| 04/02/2008 | CN101152563A Combination therapy using trefoil peptides |
| 04/02/2008 | CN101152562A Medicament combination for regrouping leech essence |
| 04/02/2008 | CN101152561A Application of Lefty protein in restraining fibrosis lesion of organ |
| 04/02/2008 | CN101152560A Segmented intestine target drug administration preparations of blood protein polypeptide and method for preparing the same |
| 04/02/2008 | CN101152559A Pharmaceutical composition having function of protecting and treating nerve damnification |
| 04/02/2008 | CN101152558A New use of LSECtin |
| 04/02/2008 | CN101152557A Preparation of aqueous extract and zymolyte of woodlousedry powder, and application of the same in medicine |
| 04/02/2008 | CN101152151A Vascellum esoderma growth factor sustained-release corpuscle and method for preparing the same |
| 04/02/2008 | CN100378223C Pylorus screw bacterium fenestra element having adhesion function |
| 04/02/2008 | CN100378219C Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor |
| 04/02/2008 | CN100378123C Chimeric chains that code for proteins that induce effects directed against viruses |
| 04/02/2008 | CN100378121C Isolated peptides corresponding to amino acid sequences of NY-ESO-1, wherein bind to MHC class I and MHC class II molecules, and uses thereof |
| 04/02/2008 | CN100378087C Novel ascorbic acid compounds, methods of synthesis and application use thereof |
| 04/02/2008 | CN100378063C Novel compounds and medicinal use thereof |
| 04/02/2008 | CN100377745C Stabilized medicine preparation form with by porous kietyoite covering flavour |
| 04/02/2008 | CN100377742C Pharmaceutical formulation comprising low molecular weight thrombin inhibitor and its prodrug |
| 04/02/2008 | CN100377741C Compound bone peptide for injection and its preparation process |
| 04/02/2008 | CN100377740C Therapeutic uses of beta-casein A2 and dietary supplement containing beta-casein A2 |
| 04/02/2008 | CN100377710C Aromatase inhibition to enhance assisted reproduction |
| 04/01/2008 | US7351840 Perindopril |
| 04/01/2008 | US7351816 Nucleic acid encoding anti-IgE antibodies |
| 04/01/2008 | US7351815 Canine pre-proGHRH and mature GHRH genes |
| 04/01/2008 | US7351813 Expression vector coding heterologous protein for use in human therapeutics; for treatment of blood nd liver disorders |
| 04/01/2008 | US7351811 Gene SCC-112 and diagnostic and therapeutic uses thereof |
| 04/01/2008 | US7351810 Polypeptides, polynucleotides and uses thereof |
| 04/01/2008 | US7351800 Stabilized albumin preparations |
| 04/01/2008 | US7351794 PRO1754 polypeptides |
| 04/01/2008 | US7351793 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and tumor disorders |
| 04/01/2008 | US7351792 G-protein coupled receptor for use as tool in identify modulators which prevent serine protease activation in response to trauma and immune system attack |
| 04/01/2008 | US7351791 Intermediate for preparing glycopeptide derivatives |
| 04/01/2008 | US7351790 Peptide-based compounds |
| 04/01/2008 | US7351741 4-(4-chloro2-hydroxybenzoylamino)butyric acid or salts for delivering an agent that would otherwise be destroyed or rendered less effective by conditions encountered before the agent reaches its target zone |
| 04/01/2008 | US7351721 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them |
| 04/01/2008 | US7351701 Therapeutic compounds |
| 04/01/2008 | US7351697 Tumor-specific vector for gene therapy |
| 04/01/2008 | US7351694 Diagnosis of prostate cancer; genetic engineered protein |
| 04/01/2008 | US7351693 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 04/01/2008 | US7351692 Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| 04/01/2008 | US7351691 Bactericides with antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals |
| 04/01/2008 | US7351690 Knockout identification of target-specific sites in peptides |
| 04/01/2008 | US7351688 Compositions and methods for less immunogenic protein formulations |
| 04/01/2008 | US7351687 Peptide structure containing lanthionine and methyllanthionine as constituents isolated from Microbispora sp. ATCC PTA-5024; methicillin resistant and vancomycin resistant bacteria; M. catharralis, Neisseria species and H. influenzae and Mycobacteria |
| 04/01/2008 | US7351686 Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| 04/01/2008 | US7351583 Antibodies to G protein-coupled receptor |
| 04/01/2008 | US7351577 For hemophilia gene therapy |
| 04/01/2008 | US7351566 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 04/01/2008 | US7351561 Thrombin preparations and process for their production |
| 04/01/2008 | US7351555 Expression vector comprising nucleotide sequences coding cytokine receptor (Zcytor16) for use as antagonist tool of interleukin-10 related t-cell derived inducible factor in diagnosis, treatment and prevention of cell proliferative and inflammatory disorders |
| 04/01/2008 | US7351552 Modified pro-α peptides and their uses |
| 04/01/2008 | US7351551 Adipocyte differentiation-associated gene and protein |
| 04/01/2008 | US7351535 Using cholesterol transport protein to identify modulators which enhance high density lipoprotein concentration in blood |
| 04/01/2008 | US7351526 Using configuration changes/variations in protein as diagnostic/prognostic indicator of spongiform and nervous system disorders |
| 04/01/2008 | US7351524 Diagnostics and therapeutics for macular degeneration-related disorders |
| 04/01/2008 | US7351427 Biodistribution and reduced side effects; for parenteral administration |
| 04/01/2008 | US7351422 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same |
| 04/01/2008 | US7351414 Administering parathyroid hormone; crystal proteins; for treatment of osteoporosis |
| 04/01/2008 | US7351411 Administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component |
| 04/01/2008 | US7351410 Glycogen storage disease type II treatment comprising human acid glucosidase, mannitol and sucrose in aqueous solution |
| 04/01/2008 | US7351409 Tumor antigens and CTL clones isolated by a novel procedure |
| 04/01/2008 | CA2305623C Porcine circovirus, vaccines, and diagnostic reagents |
| 04/01/2008 | CA2294099C Absorption of minerals |
| 04/01/2008 | CA2291074C Composition and method for enhancing transport across biological membranes |
| 04/01/2008 | CA2278546C Freeze-dried composition of bone morphogenetic protein human mp52 |
| 04/01/2008 | CA2213368C Polyetherester copolymers as drug delivery matrices |
| 04/01/2008 | CA2175992C In situ modification and manipulation of stem cells of the central nervous system |
| 04/01/2008 | CA2140010C Blood coagulation normalizer containing tcf-ii as active ingredient |
| 03/27/2008 | WO2008036761A2 Anti-microbial defensin-related peptides and methods of use |
| 03/27/2008 | WO2008036717A2 Use of soluble galectin-3 (gal-3) for cancer treatment |
| 03/27/2008 | WO2008036682A2 Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| 03/27/2008 | WO2008036565A1 Tripeptides for treating cancer metastasis, prostate cancer and melanoma |
| 03/27/2008 | WO2008036429A1 Gallium compositions for the treatment of liver cancer and methods of use |
| 03/27/2008 | WO2008036293A1 Pulmonary surfactant formulations and methods for promoting mucus clearance |
| 03/27/2008 | WO2008036292A2 Method for treating otitis externa |
| 03/27/2008 | WO2008036271A1 Formulations for therapeutic administration of thyroid stimulating hormone (tsh) |
| 03/27/2008 | WO2008036258A2 Collyrium for dry eye |
| 03/27/2008 | WO2008036244A1 Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
| 03/27/2008 | WO2008036157A2 Prophylactic and therapeutic treatment of avian influenza infections in animals |
| 03/27/2008 | WO2008036003A1 Pharmaceutical inhalation composition |
| 03/27/2008 | WO2008035894A1 Antiviral agent against animal viruses |
| 03/27/2008 | WO2008035823A1 Cell death inhibitor |
| 03/27/2008 | WO2008035371A2 Dietary anti-bacterial compositions |
| 03/27/2008 | WO2008035370A2 Compositions for prevention and treatment of mastitis and metritis |
| 03/27/2008 | WO2008035328A2 Method of organism rejuvenation |
| 03/27/2008 | WO2008035243A2 Composition for treatment of burns and wounds |
| 03/27/2008 | WO2008035172A2 Pharmaceutical compositions containing desmopressin |
| 03/27/2008 | WO2008035093A2 Peptides |
| 03/27/2008 | WO2008035001A2 Composition for the treatment of amyotrophic lateral sclerosis |
| 03/27/2008 | WO2008034881A1 Protease resistant insulin analogues |
| 03/27/2008 | WO2008034866A2 Dbait and uses thereof |
| 03/27/2008 | WO2008034637A1 Methods involving lef-1 regulation and use of lef-1 or compounds altering lef-1 signalling for treating or preventing diseases |
| 03/27/2008 | WO2008034623A2 Medicament for the prophylaxis, treatment or diagnosis of ischaemic diseases |
| 03/27/2008 | WO2008034621A2 Nucleotide phosphorylase for the prophylaxis, treatment or diagnosis of acute lung injury (ali) |
| 03/27/2008 | WO2008034608A1 The death receptor cd95 controls neurogenesis of adult neural stem cells in vivo and in vitro |
| 03/27/2008 | WO2008034346A1 Composition and method for treating tumor |
| 03/27/2008 | WO2008034316A1 Compound preparation capable of reducing oxidative stress rapidly and the preparative method thereof |
| 03/27/2008 | WO2008034162A1 Compositions and uses thereof in the treatment of wounds |
| 03/27/2008 | WO2008034161A1 Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor |
| 03/27/2008 | WO2008019144A3 Threapeutic methods for treating vascular eye disorders with dll4 antagonists |